Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

Sponsor
Hunan Cancer Hospital
Study ID
NCT06840704
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oral immunonutrition — DIETARY_SUPPLEMENT
    Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.

Study Details

This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.

Key Dates

First listed
Feb 21, 2025
Start date
Feb 25, 2025
Status verified
Mar 2026
Primary completion
Jun 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
121 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Oral immunonutrition
    Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.
  • No Intervention: Standard nutrition
    If the patient has concurrent nutritional risks, routine nutritional therapy (no immunonutrition) can be provided under the guidance of a nutritionist.

Primary Outcome Measure

Incidence rate of grade 2 or higher acute esophagitis [ Time Frame: 3 months ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies